Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

NCT05594927 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Icaritin
DRUG: Huachansu

Sponsor

Beijing Shenogen Biomedical Co., Ltd